Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 55.21

-3.0%

9:55 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (10336)	2/8/2004 11:56:43 AM
From: quidditch	Read Replies (2) of 52153

Peter, <<The mean reduction in viral load at the end of the treatment phase ranged from 1.67 log10 copies/mL to 1.77 log10 copies/mL....>> Sincy my last logging of log10 was in calculating molalities and molarities in HS chemistry, how does that translate into understandable quantitative measure--in particular--what is the significance of the use of "copies/mL"? Second, I thought that the exercise of decoding the APHT pr was very useful, very constructive. Thanks. Even as BTs obviously have to present results of pre-clinical and clinical trial and other information in accepted scientific and statistical language and format, it becomes clear after an exercise such as that how BTs to one degree or another cloak the disclosure in such language/format to conceal as often as to reveal. ALXN comes to mind in how much information is given without a baseline preliminary assessment and characterization. Between the occasional "we are disappointed by these results but continue to believe that xxxx [molecule] has therapeutic properties that will be shown to be useful in xxxx regimen...." and the "we are delighted that these results confirm our belief that...", there is a world of hazy gray. It's kind of like what you make of inconclusive evidence of WMD and what you do with it. On that score, do you think that trial protocols are designed, in some cases, to prolong the clinical exercise (i.e., delay killing off the compound and preserve funding) when a more rigorous design might indeed show lack of efficacy? quid

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next